bicalutamide has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlm, C; Allard, A; Angelin, M; Balkhed, ÅÖ; Becker, M; Bjartell, A; Bremell, D; Buckland, R; Carlsson, CT; Connolly, AF; Fonseca-Rodríguez, O; Freyhult, E; Gisslén, M; Henningsson, AJ; Josefsson, A; Lenman, A; Lindquist, E; Nilsson, AC; Niward, K; Överby, AK; Repo, J; Robinsson, D; Rosendal, E; Rudolfsson, S; Stranne, J; Styrke, J; Welén, K | 1 |
1 trial(s) available for bicalutamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Benzamides; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Female; Hospitalization; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Retrospective Studies; SARS-CoV-2; Sweden; Testosterone; Tosyl Compounds; Treatment Outcome | 2022 |